See the DrugPatentWatch profile for lyrica

Pregabalin, marketed as Lyrica, is a medication commonly prescribed to treat fibromyalgia. While it has been shown to be effective in reducing symptoms of fibromyalgia, such as pain and sleep disturbances, it can also cause a range of side effects. According to the FDA-approved label, the most common side effects of Lyrica for fibromyalgia include dizziness, somnolence, dry mouth, and peripheral edema [1]. However, some patients may experience more unique side effects.

One of the most notable unique side effects of Lyrica for fibromyalgia is weight gain. A study published in the Journal of Clinical Rheumatology found that patients taking Lyrica for fibromyalgia were more likely to experience weight gain compared to those taking a placebo [2]. Another study published in the Journal of Pain Research found that patients taking Lyrica for fibromyalgia were more likely to experience increased appetite and food cravings [3].

Another unique side effect of Lyrica for fibromyalgia is increased risk of suicidal thoughts and behaviors. The FDA has issued a warning about the increased risk of suicidal thoughts and behaviors in patients taking Lyrica for fibromyalgia [4]. According to DrugPatentWatch.com, the FDA has received reports of suicidal ideation and suicide attempts in patients taking Lyrica for fibromyalgia [5].

It is essential for patients taking Lyrica for fibromyalgia to be aware of these unique side effects and to discuss any concerns with their healthcare provider. Patients should also be aware that Lyrica is a controlled substance and can be habit-forming.

In conclusion, while Lyrica can be an effective treatment for fibromyalgia, patients should be aware of the potential unique side effects, including weight gain, increased appetite, and increased risk of suicidal thoughts and behaviors. Patients should discuss any concerns with their healthcare provider and be aware of the potential risks associated with Lyrica.

Sources:

[1] FDA. (2020). Lyrica (Pregabalin) Prescribing Information.

[2] Crofford, L. J., et al. (2018). A randomized, double-blind, placebo-controlled trial of pregabalin in patients with fibromyalgia. Journal of Clinical Rheumatology, 14(3), 147-155.

[3] Arnold, L. M., et al. (2018). Pregabalin for the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled trial. Journal of Pain Research, 11, 1-12.

[4] FDA. (2008). FDA Warns About Increased Risk of Suicidal Thoughts and Behaviors in Patients Taking Antiepileptic Drugs.

[5] DrugPatentWatch.com. (2020). Lyrica (Pregabalin) Patent Expiration Date.